NASDAQ$ALKS

Alkermes plc · Q4 2021 earnings

Q4 2021 earnings · · Investor relations

Briefing

Alkermes reported financial results for the fourth quarter and year ended Dec. 31, 2021.

Alkermes reported Q4 2021 revenues of $324.5 million and GAAP net income of $0.9 million, or $0.01 per share. Non-GAAP net income was $38.5 million, or $0.23 per share. The company provided financial expectations for 2022, reflecting a focus on proprietary products and continued operating efficiency.

  • Total revenues for the quarter were $324.5 million.
  • GAAP net income was $0.9 million for the quarter, or a basic and diluted GAAP earnings per share of $0.01.
  • Non-GAAP net income was $38.5 million for the quarter, or a non-GAAP basic earnings per share of $0.24 and diluted earnings per share of $0.23.
  • Alkermes recorded cash, cash equivalents and total investments of $765.7 million at Dec. 31, 2021.

Headline financials

Total Revenue

$324M

Previous: $280M+15.9%
EPS (adj)

$0.23

Previous: $0.10+130.0%
Capital Expenditures

$8.66M

Previous: $5.44M+59.2%
Free Cash Flow

$22.4M

Previous: $61.9M-63.9%
Net Income

$873K

Previous: -$42.6M+102.0%
Operating Income

$2.38M

Previous: -$30.7M+107.8%
Gross Profit

$172M

Previous: $125M+38.0%
Cash & Equivalents

$338M

Previous: $660M-48.8%
Total Assets

$2.02B

Previous: $1.95B+3.8%
Stock-Based Comp

$19M

Previous: $24.9M-23.6%

Revenue & EPS history

Alkermes · Revenue · Quarterly

$324M

Q4 2021+15.9%vs Q4 2020
Beat estimate in 11 of 16 quarters(69%)
ActualEstimate

Revenue by segment

Alkermes · $206M total across 4 segments · Q4 2021

  • VIVITROL
    $92M+15.0%
  • ARISTADA
    $78.7M+14.1%
  • VUMERITY
    $26.9M
  • LYBALVI
    $8.22M

Forward guidance

Alkermes provided financial expectations for 2022, assuming improvement in COVID-19 pandemic-related disruptions beginning in the second quarter and reflecting the removal of all royalties from worldwide sales of the long-acting INVEGA products beginning in 2022.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2021

Historical avgQ4 2021

-0.6%

Avg return

Earnings day

-0.0%

Avg return

5 days after

-0.5%

Avg return

30 days after

45%

27 / 60 earnings

Positive

+16.6%

Q4 2017

Best reaction

-14.8%

Q1 2020

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+6.2%+2.5%+27.0%
Q4 2025-6.6%-9.4%-12.0%
Q3 2025+3.9%+3.3%+0.0%
Q1 2025+6.3%+5.5%+6.4%
Q4 2024+4.8%+12.3%+6.5%
Q3 2024-6.3%-5.1%+3.3%
Q2 2024+12.2%+11.7%+11.8%
Q1 2024-2.8%-1.8%-4.6%
Q4 2023+15.0%+8.6%+2.7%
Q3 2023-2.4%-4.0%-3.7%
Q2 2023-1.8%-5.1%-11.9%
Q1 2023-7.1%-6.1%-3.9%
Q4 2022+4.0%+2.9%-3.6%
Q3 2022+3.8%+0.3%+12.2%
Q2 2022-9.7%-14.4%-16.5%
Q1 2022+9.8%+6.4%+12.5%
Q4 2021+8.8%+7.6%+12.1%
Q3 2021-8.2%-5.0%-28.7%
Q2 2021+5.9%+11.6%+28.9%
Q1 2021-3.2%-1.6%+0.8%
Q4 2020-11.8%-13.7%-15.3%
Q3 2020+5.6%+5.9%+20.2%
Q2 2020-8.8%-7.4%-19.0%
Q1 2020-14.8%-14.7%+1.6%
Q4 2019-7.0%-7.8%-15.5%
Q3 2019+5.7%+6.0%+13.9%
Q2 2019-10.2%+1.2%-12.3%
Q1 2019-12.2%-12.7%-31.1%
Q4 2018-1.2%+3.6%+3.3%
Q3 2018+3.0%+6.5%-11.6%
Q2 2018-0.1%-0.3%+2.0%
Q1 2018+1.5%+1.4%+3.9%
Q4 2017+16.6%+23.0%+12.0%
Q3 2017+0.7%-1.5%+3.2%
Q2 2017-4.1%-5.4%-12.4%
Q1 2017+2.0%+2.4%+1.0%
Q4 2016-2.9%-4.6%+3.7%
Q3 2016-1.4%+4.0%+8.4%
Q2 2016-3.6%-6.0%-14.1%
Q1 2016-2.0%
Q4 2015-1.4%
Q3 2015+7.6%
Q2 2015+2.4%
Q1 2015+3.1%
Q4 2014-3.4%
Q3 2014+7.7%
Q2 2014-7.2%
Q1 2014+3.2%
Q4 2013-7.7%
Q3 2013-3.7%
Q2 2013+3.5%
Q1 2013+3.9%
Q4 2010-1.0%
Q4 2012-9.9%
Q3 2012+2.2%
Q3 2011+2.2%
Q2 2011-7.7%
Q2 2012-7.7%
Q4 2011-7.7%
Q2 2010-3.0%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro